Rgc Upcoming Deadline: Faruqi & Faruqi Reminds - May 15

The Story

Faruqi & Faruqi, LLP has reminded Regencell Bioscience shareholders that the securities class action filing deadline is June 23, 2026. The firm says investors who purchased $RGC securities between October 28, 2024 and October 31, 2025 may be eligible to participate and encourages affected parties to contact Securities Litigation Partner James (Josh) Wilson directly to discuss options.

This notice highlights active litigation risk for $RGC holders and defines the pool of potential claimants ahead of a firm deadline that could determine eligibility for any future recovery.

Why It Matters For Your Portfolio

• Deadline Impact: June 23, 2026 is the last day to join the class, missing it could bar recovery of losses and change your realistic recovery outlook for $RGC positions.
• Eligibility Window: Purchases from Oct 28, 2024 to Oct 31, 2025 define who can file, which affects the size of the claimant pool and potential settlement math.
• Valuation Inputs: Multiple data points are available for valuation analysis, including 19534.74%, 1301.24% and 16.68%, which investors can use when modeling damages and downside risk.
• Volatility Risk: Ongoing litigation and related filings may increase $RGC share volatility and influence how you weigh exposure to biotech legal events in your portfolio.

The Trade

Who should care: shareholders who owned $RGC during the eligibility window and investors tracking legal risk in small-cap biotech. Watch next: the June 23, 2026 filing deadline, new court filings or motions, and company disclosures that could change case scope.

This information is for informational purposes only and not legal or investment advice. Analysts note that litigation timelines and settlements often affect volatility and valuation, so monitor official notices and counsel communications closely.